Address: (Linghao Road) No.2 Street, No.20 Economic Development Zone, Hangzhou
CARDIAC DRUG ELUTING STENT SYSTEM Products Our Drug-eluting stents (DES) are a standard metallic coronary stent with a polymer coating and paclitaxel, which allows drug elution into the coronary wall for weeks to months after stent implantation. Drug-eluting stent is an advanced workhorse DES......Send Inquiry
CARDIAC DRUG ELUTING STENT SYSTEM
Our Drug-eluting stents (DES) are a standard metallic coronary stent with a polymer coating and paclitaxel, which allows drug elution into the coronary wall for weeks to months after stent implantation. Drug-eluting stent is an advanced workhorse DES ready for your challenging coronary cases.
Drug-eluting stents prevent a coronary artery from narrowing again after angioplasty. They are coated with medicine that prevents scar tissue from growing into the artery.
Stents are small, expandable tubes that are inserted during angioplasty into a narrowed or blocked section of the coronary artery to open the artery and improve blood flow.
Drug-eluting stents are used more often than bare-metal stents.
Flexible stent platform for outstanding flexibility and conformability.
A single strand of cobalt alloy is formed into a sinusoid, wrapped in a helical pattern, and laser fused.
Thinner struts with enhanced stent visibility for accurate stent placement
How do drug-eluting stents work?
All stents have a risk that scar tissue will form and narrow the artery again. This scar tissue can block blood flow. But drug-eluting stents are coated with drugs that prevent scar tissue from growing into the artery. Drug-eluting stents may lower the chance that you will need a second procedure (angioplasty or surgery) to open the artery again.
Paclitaxel is slowly released into the intimal tissue of the coronary artery to prevent cell proliferation and neointimal hyperplasia. When deployed in patients with previously untreated coronary artery lesions, the paclitaxel-eluting stent (PES) effectively reduces the need for revascularization without increasing the risk of in-stent thrombosis. While long-term outcomes data and comparative efficacy and cost-benefit trials versus other drug-eluting stents are required, the PES appears to be an attractive alternative for the management of de novo coronary artery lesions.